JPWO2020252421A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020252421A5 JPWO2020252421A5 JP2021573426A JP2021573426A JPWO2020252421A5 JP WO2020252421 A5 JPWO2020252421 A5 JP WO2020252421A5 JP 2021573426 A JP2021573426 A JP 2021573426A JP 2021573426 A JP2021573426 A JP 2021573426A JP WO2020252421 A5 JPWO2020252421 A5 JP WO2020252421A5
- Authority
- JP
- Japan
- Prior art keywords
- fusion protein
- substitutions
- amino acid
- antibody
- variant polypeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962861484P | 2019-06-14 | 2019-06-14 | |
| US62/861,484 | 2019-06-14 | ||
| PCT/US2020/037648 WO2020252421A2 (en) | 2019-06-14 | 2020-06-13 | Novel interleukin-2 variants and bifunctional fusion molecules thereof |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022536347A JP2022536347A (ja) | 2022-08-15 |
| JP2022536347A5 JP2022536347A5 (https=) | 2023-08-07 |
| JPWO2020252421A5 true JPWO2020252421A5 (https=) | 2023-08-07 |
| JP7850417B2 JP7850417B2 (ja) | 2026-04-23 |
Family
ID=73782254
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021573426A Active JP7850417B2 (ja) | 2019-06-14 | 2020-06-13 | 新規インターロイキン－２バリアントおよびその二官能性融合分子 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20220170028A1 (https=) |
| EP (1) | EP3983001A4 (https=) |
| JP (1) | JP7850417B2 (https=) |
| KR (1) | KR20220035122A (https=) |
| CN (1) | CN114728040A (https=) |
| AU (1) | AU2020292421B2 (https=) |
| CA (1) | CA3143038A1 (https=) |
| WO (1) | WO2020252421A2 (https=) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020057646A1 (zh) | 2018-09-21 | 2020-03-26 | 信达生物制药(苏州)有限公司 | 新型白介素2及其用途 |
| MX2022007712A (es) * | 2019-12-17 | 2022-09-26 | Amgen Inc | Agonista doble de interleucina-2/receptor de tnf para uso en terapia. |
| US11633488B2 (en) | 2020-01-10 | 2023-04-25 | Bright Peak Therapeutics Ag | Modified IL-2 polypeptides and uses thereof |
| JP7748393B2 (ja) | 2020-05-08 | 2025-10-02 | アルパイン イミューン サイエンシズ インコーポレイテッド | Ａｐｒｉｌおよびｂａｆｆ阻害免疫調節タンパク質、ならびにその使用方法 |
| TWI815194B (zh) | 2020-10-22 | 2023-09-11 | 美商基利科學股份有限公司 | 介白素2-Fc融合蛋白及使用方法 |
| US20240199714A1 (en) * | 2021-04-16 | 2024-06-20 | Orionis Biosciences, Inc. | Il-2 based constructs |
| WO2023281485A1 (en) * | 2021-07-09 | 2023-01-12 | Bright Peak Therapeutics Ag | Modified il-2 polypeptides for treatment of inflammatory and autoimmune diseases |
| KR20240082364A (ko) * | 2021-09-22 | 2024-06-10 | 포트비타 바이오로직스 (싱가포르) 피티이. 리미티드 | 인터루킨-2 돌연변이 및 이의 융합 단백질 |
| US20240376172A1 (en) * | 2021-10-06 | 2024-11-14 | Iltoo Pharma | Interleukin 2 chimeric constructs with targeting specificy to inflamed tissues |
| WO2023154785A2 (en) * | 2022-02-10 | 2023-08-17 | Orionis Biosciences, Inc. | Il-2 trap molecules |
| US20250215452A1 (en) | 2022-03-25 | 2025-07-03 | Universität Zürich | Adenoviral Mediated Targeting of Activated Immune Cells |
| CA3259108A1 (en) | 2022-06-16 | 2023-12-21 | Cephalon Llc | Attenuated Anti-PD1-IL2 Immunoconjugates and Their Uses |
| EP4582455A4 (en) * | 2022-08-29 | 2026-03-25 | Jiangsu Hengrui Pharmaceuticals Co Ltd | Fusion protein comprising a Taci polypeptide and its use |
| EP4689123A1 (en) * | 2023-03-29 | 2026-02-11 | WuXi Biologics Ireland Limited | Il-2 variants with improved stability and compositions thereof |
| WO2024249568A1 (en) | 2023-05-30 | 2024-12-05 | Paragon Therapeutics, Inc. | Alpha4beta7 integrin antibody compositions and methods of use |
| CN121889424A (zh) | 2023-08-14 | 2026-04-17 | 派拉冈医疗公司 | α4β7整联蛋白结合蛋白及使用方法 |
| WO2025040797A1 (en) * | 2023-08-23 | 2025-02-27 | Depth Charge Ltd | Interleukin-2 variant proteins that facilitate covalent chemical conjugation and uses thereof |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6955807B1 (en) * | 1998-05-15 | 2005-10-18 | Bayer Pharmaceuticals Corporation | IL-2 selective agonists and antagonists |
| PT1454138E (pt) * | 2001-12-04 | 2012-03-28 | Merck Patent Gmbh | Imunocitoquinas com seletividade modulada |
| CN1930300A (zh) * | 2004-03-05 | 2007-03-14 | 希龙公司 | 预测患者治疗药物耐受性的体外试验系统 |
| BRPI0508470A (pt) * | 2004-03-05 | 2007-07-31 | Chiron Corp | sistema de teste in vitro para prever toleráncia do paciente aos agentes terapêuticos |
| CN102260352B (zh) * | 2010-05-28 | 2013-11-20 | 山东先声麦得津生物制药有限公司 | 靶向性白细胞介素融合蛋白及其制备方法与应用 |
| HUE029139T2 (hu) * | 2011-02-10 | 2017-02-28 | Roche Glycart Ag | Mutáns interleukin-2 polipeptidek |
| KR102042246B1 (ko) * | 2014-02-06 | 2019-11-28 | 에프. 호프만-라 로슈 아게 | 인터류킨-2 융합 단백질 및 이의 용도 |
| KR102379464B1 (ko) * | 2016-06-20 | 2022-03-29 | 키맵 리미티드 | 항-pd-l1 항체 |
| US9567399B1 (en) * | 2016-06-20 | 2017-02-14 | Kymab Limited | Antibodies and immunocytokines |
| KR20190136076A (ko) * | 2017-04-13 | 2019-12-09 | 에프. 호프만-라 로슈 아게 | 암 치료 방법에 사용하기 위한 인터루킨-2 면역접합체, cd40 작용제 및 임의적인 pd-1 축 결합 길항제 |
| JP2020521452A (ja) * | 2017-05-24 | 2020-07-27 | パンディオン・セラピューティクス・インコーポレイテッド | 標的化免疫寛容 |
| JP2020521759A (ja) * | 2017-05-26 | 2020-07-27 | ザ・ジョンズ・ホプキンス・ユニバーシティ | 免疫トレランスを調節するための多機能性の抗体−リガンド・トラップ |
| JP7637415B2 (ja) * | 2018-06-22 | 2025-02-28 | キュージーン インコーポレイテッド | インターロイキン－２バリアントおよびその使用方法 |
| AU2020287373B2 (en) * | 2019-06-05 | 2026-01-29 | Asher Biotherapeutics, Inc. | Fusions of mutant interleukin-2 polypeptides with antigen binding molecules for modulating immune cell function |
-
2020
- 2020-06-13 CN CN202080057566.1A patent/CN114728040A/zh active Pending
- 2020-06-13 EP EP20823570.5A patent/EP3983001A4/en active Pending
- 2020-06-13 WO PCT/US2020/037648 patent/WO2020252421A2/en not_active Ceased
- 2020-06-13 US US17/618,207 patent/US20220170028A1/en active Pending
- 2020-06-13 AU AU2020292421A patent/AU2020292421B2/en active Active
- 2020-06-13 KR KR1020227001354A patent/KR20220035122A/ko active Pending
- 2020-06-13 CA CA3143038A patent/CA3143038A1/en active Pending
- 2020-06-13 JP JP2021573426A patent/JP7850417B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2020252421A5 (https=) | ||
| JP7317159B2 (ja) | キメラ抗原受容体及びその使用方法 | |
| JPWO2020252418A5 (https=) | ||
| JP6041799B2 (ja) | Ｔｒａｉｌｒ２特異的多量体足場 | |
| JP2023182757A (ja) | 調整可能な親和性を有する免疫調節タンパク質 | |
| JP6783797B2 (ja) | 抗がん融合ポリペプチド | |
| JP6918405B2 (ja) | インターロイキン２及びそれに由来するタンパク質の分泌レベルを増大させる方法。 | |
| US10919950B2 (en) | Tumor-specific IFNA secretion by car T-cells to reprogram the solid tumor microenvironment | |
| JP2020198875A5 (https=) | ||
| JP7356726B2 (ja) | タンパク性ヘテロ二量体及びその使用 | |
| CA2993891A1 (en) | Interleukin-15 fusion proteins for tumor targeting therapy | |
| JPWO2021119516A5 (https=) | ||
| JP2021028329A (ja) | タンパク質及びペプチドの免疫原性を減少させる方法 | |
| CN111423512A (zh) | 阻断血管内皮细胞生长且活化t细胞的多靶向融合蛋白和包含其的药物组合物 | |
| JP2018536434A (ja) | 腫瘍形質導入のための組成物及び方法 | |
| JP7303527B2 (ja) | 新たな結合特異性を抗体に付与する超汎用法 | |
| US20240150422A1 (en) | Il-12 fc fusion proteins and uses thereof | |
| CN112294760A (zh) | 一种液体制剂及其应用 | |
| CN113667004B (zh) | 一种白介素2突变体 | |
| US7041499B2 (en) | Immuno activation of CS1 receptor in natural killer cells to inhibit tumor cell growth | |
| CN113603791A (zh) | 一种融合蛋白及其应用 | |
| KR102857671B1 (ko) | 개과 동물의 her2 및 cd3에 특이적으로 결합하는 이중특이적 항체 및 이의 용도 | |
| CN117986383A (zh) | 融合蛋白及其应用 | |
| US20250236653A1 (en) | Targeted low potency il-12 fc fusion proteins and uses thereof | |
| RU2021139059A (ru) | Новые варианты интерлейкина-2 для лечения рака |